Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy

Abstract Background The magnitude and rapidity of the tumor response to androgen deprivation is known to predict the durability of the therapy. We have investigated the predictive value of categorizing patients by the half-life of PSA under neoadjuvant androgen deprivation therapy in patients with b...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yong Jin Kang, Won Sik Jang, Jong Kyou Kwon, Cheol Yong Yoon, Joo Yong Lee, Won Sik Ham, Young Deuk Choi
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2017-11-01
Col·lecció:	BMC Cancer
Matèries:	Prostate Neoadjuvant androgen deprivation therapy Prostate-specific antigen
Accés en línia:	http://link.springer.com/article/10.1186/s12885-017-3775-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!